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A Morel-Lavalle´e lesion occurs as a result of a closed degloving
injury that is not adequately managed in the acute setting. Patients
report a localised swelling following trauma, often over a boney
prominence, which causes pain and may have associated overlying
skin changes and numbness.1 Traumatic shearing forces separate
the skin and subcutaneous tissue from the underlying fascia. This
disrupts perforating vessels and nerves and creates a potential
space that acutely ﬁlls with blood, lymph and fat, both necrotic and
viable. The acute haematoma, if not evacuated, may necrose the
overlying skin if large or, if smaller and the skin survives, will
develop into a chronic swelling with a well deﬁned capsule – the
Morel-Lavalle´e lesion. Victor Morel-Lavalle´e, a French surgeon,
was the ﬁrst to describe post traumatic subcutaneous ‘effusions’of
the tissues over the greater trochanter in 1853.3 Since this
description his name is now eponymous with all degloving type
injuries regardless of location.
The imaging modality of choice is magnetic resonance imaging
(MRI). Findings include a well-deﬁned lesion with tapering
margins that fuse with adjacent fascial planes. The MRI may
demonstrate a ﬂuid-ﬂuid level, a loculated collection and
frequently a capsule.2
The management of Morel-Lavalle´e lesions has included
conservative compressive dressings, percutaneous drainage and
surgical debridement.7,6 More recently, sclerodesis using doxycy-
cline or alcohol has been described.5,4
None of the management strategies described to date have been
particularly successful. We propose the use of Tisseel1, a Fibrin
sealant, as a treatment option and report two cases. Tisseel1 is a
two-component ﬁbrin sealant made from pooled human plasma.
When combined, the two components mimic the ﬁnal stage of the
blood coagulation cascade. It is currently indicated for use as an
adjunct to haemostasis and is often used in the application of
skin grafts as it renders them more resistant to shearing forces
that could result in graft loss. The theory behind recurrence of* Corresponding author. Tel.: +44 1912336161.
E-mail address: jetwokes@doctors.org.uk (J.E.T. Wokes).
1572-3461 2012 Elsevier Ltd. 
http://dx.doi.org/10.1016/j.injury.2012.09.016
Open access under the Elsevier OA license.Morel-Lavalle´e lesions is incomplete excision of the lesion or
obliteration of the potential space leading to re-accumulation of
the haemo-serous ﬂuid. We hypothesized that after excision of the
lesion capsule, the use of a ﬁbrin sealant would enhance successful
elimination of the space therefore preventing recurrence.
2. Technique
A preoperative MRI scan was performed to delineate the
internal anatomy of the lesions and plan the surgical approach.
The surgical procedure involved incision through the soft-
tissues directly over the lesions with subsequent excision of the
lesion and capsule whole. Haemostasis was assured and the cavity
thoroughly washed out. A percutaneous drain was inserted before
the application of Tisseal1 to the entire surface of the cavity.
Manual compression was then applied for 5 min before the skin
was closed in layers and a pressure garment was ﬁtted. Post-
operatively the patients were mobilised early and the drains wereFig. 1. Pre-operative photographs.
Fig. 2. Pre-operative photographs.
Fig. 3. Preoperative MRI.
Fig. 4. Preoperative MRI.
Fig. 5. Intra-operative photographs.
Fig. 6. Intra-operative photographs.
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three weeks in total. Follow-up consisted of reviews at 1, 3, 12 and
24 weeks after discharge.
3. Case report
Case 1 – a 52 year-old gentleman who presented with a large,
uncomfortable swelling on his left ﬂank secondary to a road trafﬁc
collision 18 years prior to referral. Previous surgical drainage had
been undertaken at the time of the injury but the swelling had
recurred (Figs. 1 and 2).
X-rays taken by the Orthopaedic surgeons revealed no bony
abnormality and he was referred to the plastic surgery team with
the preliminary diagnosis of a soft-tissue sarcoma. An MRI revealeda two ‘multi-loculated haemorrhagic ﬂuid collections with features
consistent with a Morel-Lavalle´e lesions’ (Figs. 3–6).
Histology reported a cystic lesion with no evidence of
cellular atypia or malignancy. The patient did not develop any
Fig. 8. Post-operative photographs.Fig. 7. Post-operative photographs.
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clinical resolution at 6 months post-operation (Figs. 7 and 8).
4. Discussion
Morel-Lavalle´e lesions are problematic for both patients and
surgeons alike. Successful management of such lesions is difﬁcult.
Extensive debridement alone often results is post-operative
complications and recurrence. Although recalcitrant Morel-Laval-
le´e lesions can successfully be treated with doxycycline or alcohol
sclerodesis these management strategies do not stimulate the
natural wound healing process and entail the introduction of a
synthetic compound. There are potential complications with the
use of alcohol or doxycycline such as skin burns and allergic
reactions that are not risks with the use of a ﬁbrin sealant. Given
the promising results we have seen, a combination of surgical
excision of the lesion and the application of a ﬁbrin sealantrepresents a viable option in the management of Morel-Lavalle´e
lesions.
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